An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment
This Clinical Access Program has been set up to make sure patients in the United States who have been receiving and benefiting from the study drug Gefitinib (IRESSA) will have the option of continuing to receive it after September 30, 2011. Through this study, you can continue to receive the study drug as long as your doctor continues to order it for you.
1. Male or female aged 18 years and over.
2. Patients who are currently receiving and benefiting or have previously benefited
from treatment with gefitinib through the IRESSA™ Access Program or patients
enrolled in an IND clinical trial that was IRB approved before 17 June 2005 and
who are currently benefiting or have benefited from treatment with gefitinib.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will continue to receive the study drug until you and the investigator determine that you should stop taking it.
Knight Clinical Trials Information Line